DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click HERE
to register or log in.
Tamoxifen and Aromatase Inhibitors: Cognitive Function in Occupationally Active Breast Cancer Survivors
Uniformed Services University Of The Health Sciences Bethesda United States
Pagination or Media Count:
Previous research has suggested that endocrine therapy to inhibit growth of breast cancer tissue is positively associated with cognitive limitations in breast cancer survivors BCS. Whether this relationship exists in occupationally active survivors is unknown. This study examined endocrine therapy and cognitive function in working BCS, an average of 3 years post-primary treatment. Seventy-seven BCS with past or current exposure to endocrine therapy tamoxifen or aromatase inhibitors and 56 BCS with no history of endocrine therapy completed measures of perceived and performance-based cognitive function, physical fatigue, anxiety and depression.
APPROVED FOR PUBLIC RELEASE